Lavipharm expects significant revenue/profit from the distribution of the drug DUROGESIC® in many European countries.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
It continues the procedures for transferring the marketing authorizations of DUROGESIC® to other markets and estimates that the relevant approvals will be completed in the near future.